Evalution On Efficacy Of Favipiravir For Treatment of Covid-19 At Kutkhaopun Hospital Ubonratchathani Province

Abstract

Favipiravir (FPV) was approved  for treatment of Covid-19. Favipiravir is a type of RNA-dependent RNA polymerase(RdRp). The purpose of this study was to assess the efficacy of favipiravir in treatment of Covid-19. Data were collected between July and September 2021 including 132 patients with Covid-19. The results revealed that most of the patients were  female (56.8%) , mean age was 39.12±1.09 years and mean weight was 68.68±1.52 kg, with stage 1 renal function (eGFR greater than 90 ml/min) ( 69.7%),dose of favipiravir were 1,800 mg every 12 hours on the first day and 800 mg every 12 hours on days 2–5 (86.4%) and severity of  disease was level 3.2 (50%). Most of patients had a clinical improvement (88.6%), oxygen saturation ³ 96% without supplemental oxygen (91.7%), body temperature ≤ 37.5 °C (95.5%), respiratory rate ≤ 20 breaths/minute (91.7%). The mean time to improvement of lung X-ray results after the drug was 4.63±2.7 days. The most common adverse reactions were headache (0.8%). The result of this study  shown that favipiravir was efficacy to treatment COVID-19 patients in Kut Khao Pun Hospital Ubon Ratchathani Province

Keywords : Favipiravir; Efficacy